Thomas Dyrberg
Partner @ Novo Holdings
Thomas Dyrberg is a Series B investor at Novo Holdings focused on Biotechnology and Medical. Thomas P. Dyrberg, M.D., Ph.D., serves as Senior Partner of Novo Ventures and Novo A/S. Thomas Dyrberg joined Novo A/S in December 2000, where he was a Partner.He held research positions at the Hagedorn Research Institute, Gentofte, Denmark and at the Scripps Research Institute, La Jolla, California.In 1990, he joined Novo NordiskA/S and worked in health care discovery on various aspects of diabetes immunology and pathogenesis and health Care Clinical Drug Development as an International Clinical Project Manager since 1996. He serves as the Deputy Chairman of Veloxis Pharmaceuticals A/S and has been its Director since September 2003.Thomas Dyrberg has been a Director at Gloucester Pharmaceuticals, Inc. since August 25, 2009. He serves as a Director at Rejuvenon, Corp, Allocure Inc., Veloxis, Lux Biosciences, Inc., Ophthotech Corporation, Sapphire Therapeutics Inc., and Delenex Therapeutics AG.He served as a Director of BioMimetic Therapeutics, Inc. from May 2001 to June 21, 2007. He served as a Director of Helsinn Therapeutics (U.S.), Inc. He has published several articles within the fields of diabetes, immunology, and autoimmunity.Thomas Dyrberg has an M.D. degree in 1981 and his DM.Sc. degree from the University of Copenhagen in 1986.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries Thomas Dyrberg invests in
Stages Thomas Dyrberg invests in
Countries Thomas Dyrberg invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 9 (53%)
- Medical 6 (35%)
- Health Care 5 (29%)
- Therapeutics 5 (29%)
- Life Science 3 (18%)
Stage
- Series B 5 (29%)
- Series C 3 (18%)
- Seed 1 (6%)
- Series A 1 (6%)
- Series D 1 (6%)
Country
- United States 7 (41%)
- United Kingdom 2 (12%)
- Switzerland 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Pangaea Data provides a machine learning-based software solution making scientific and clinical data more meaningful. | Seed / Jan 28, 2021 | ||
| Freeline is a clinical biotechnology company that develops transformative adeno-associated virus-vector-mediated systemic gene therapies. They use a designed AAV vector and capsid along with novel promoters and transgenes to deliver a functional copy of a therapeutic gene into human liver cells to express a functional level of the missing ordysfunctional protein into the patient’s bloodstream. Their development programs including clinical trials focus on developing products. | $80M / Series C / Jun 30, 2020 | ||
| Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient’s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully.Today, significant progressis being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy. | $23.9M / Series B / May 27, 2016 | ||
| Galera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapy is used in patients with cancer. Galera’s lead product candidate is GC4419, a highly selective and potent smallmolecule superoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. GC4419 achieved positive results in a Phase 2b clinical trial, which demonstrated its ability to reduce the incidence and duration of radiation-induced severe oral mucositis in patients with head and neck cancer, it's lead indication. The U.S. Food and Drug Administration granted Fast Track and Breakthrough Therapy designations to GC4419.The company was established in 2009 and is headquartered in Malvern, Pennsylvania, United States. | $37M / Series B / Oct 14, 2015 | ||
| Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient’s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully.Today, significant progressis being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy. | $45M / Series B / Apr 15, 2014 | ||
| Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technologydelivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity. | $8M / Series A / Nov 06, 2013 | ||
| IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases. | $50M / Private Equity / May 29, 2013 | ||
| IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases. | $125M / Private Equity / May 25, 2013 | ||
| AlloCure is a biotechnology company, develops cell therapies for the treatment of various kidney diseases, organ transplants, and multi-organ injuries. It offers biological therapeutics for acute kidney injuries. AlloCure is based in Burlington, Massachusetts. It has operations in Salt Lake City, Utah, and Hamburg, Germany.The company isdedicated to the development of off-the-shelf biological therapies to treat serious and debilitating diseases that afflict millions of people around the world. AlloCure's unique technology uses processed cells derived from human bone marrow to treat a wide variety of diseases. AlloCure was founded on the unique and proprietary technology developed by Dr. Christof Westenfelder and Dr. Axel Zander. Westenfelder and Zander are world-renowned scientists who have dedicated their careers to developing effective therapies for kidney disease. AlloCure has operations in Salt Lake City Utah and Hamburg Germany. | $25M / Series B / Apr 02, 2012 | ||
| Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technologydelivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity. | $19.3M / Series A / May 03, 2011 | ||
| See all 17 investments → | |||
Co-Investors
About Novo Holdings
Novo Holdings is a holding and investment firm that manages the assets of the Novo Nordisk Foundation. It is a life science investor with a diverse portfolio that includes equities, bonds, real estate, infrastructure, and private investments.
Novo Holdings Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Emmanuelle Coutanceau
Partner Novo Seeds
|
|||
Steve Collins
National Account Executive
|
|||
|
Thomas Dyrberg
Partner
|
|||
Thomas Grotkjær
Investor & Principal
|
|||
Abhijeet Lele
Senior Partner and Head of US Principal Investments
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Thomas Dyrberg invest in?
Thomas Dyrberg invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series C stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Thomas Dyrberg?
Public channels for Thomas Dyrberg include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Thomas Dyrberg last invest?
The most recent investment recorded for Thomas Dyrberg closed in Jan 2021. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
